|
|
 |
|
Viewing report
|
|
|
|
Ovarian Cancer Drug Pipeline Report
Life Science Analytics, June 2007, Pages: 23
Life Science Analytics, 'Ovarian Cancer Drug Pipeline Report' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of ovarian cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Customers who bought this item also bought
Ovarian Cancer Therapy Area Pipeline Report
Stakeholder Opinions: Ovarian Cancer - Beyond Carboplatin and Paclitaxel
Ovarian Cancer Therapeutics - Global Strategic Business Report
Strategic Perspectives 2001: Ovarian Cancer - Overview of Current and New Developments
Stakeholder Opinions: Ovarian Cancer Growing Importance as Secondary Indication for Targeted Therapies
Ovarian Cancer Drug Pipeline Update 2008
Ovarian Cancer Drug Pipeline Update 2009
The Cancer Market Outlook to 2012
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward
The Cancer Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
|
|
|
|
